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Human umbilical cord blood is frequently used as a source of transplantable
hematopoietic cells and more recently as a target of gene therapy – a new approach
for treatment of various disorders. The aim of our study was optimisation of the
transfection conditions of cord blood-derived CD34
+ hematopoietic cells.
Mononuclear cells fraction was isolated from cord blood samples by density gradient
centrifugation. Subsequently, CD34
+ hematopoietic cells were separated on immuno-
magnetic MiniMACS columns. Pure population of CD34
+ cells was incubated in a se-
rumfreemediumsupplementedwiththrombopoietin,stemcellfactorandFlt-3ligand
for 48 h and then transfected with plasmid DNA carrying the enhanced version of
green fluorescent protein (EGFP) as a reporter gene. We studied the influence of vari-
ous pulse settings and DNA concentrations on the transfection efficiency, measured
by flow cytometry as the fluorescence of target cells due to the expression of EGFP.
The optimal settings were as follows: 4 mm cuvette, 1600 F, 550 V/cm, and 10 go f
DNA per 500 l. With these settings we obtained a high transfection frequency
(41.2%) without a marked decrease of cell viability. An increase of the pulse capaci-
tance and/or of DNA concentration resulted in a greater electroporation efficiency,
but also in a decrease of cell viability. In conclusion, the results described here allow
one to recommend electroporation as an efficient method of gene delivery into CD34
+
hematopoietic cells derived from human umbilical cord blood.
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blood.Since the first clinical application of human
umbilical cord blood (UCB) (Gluckman et al.,
1989), there has been an increasing use of
UCB as an alternative to bone marrow and
mobilized peripheral blood source of
transplantable hematopoietic stem/progeni-
tor cells (HSPC). More than 1000 cord blood
transplantations have been performed to
date, in patients with various disorders, in-
cluding malignant diseases, bone marrow fail-
ures, hemoglobinopathies and inborn errors
of metabolism (Gluckman, 2000).
The umbilical cord blood-derived HSPC dif-
fer from their counterparts present in adult
bone marrow or in mobilized peripheral
blood. The content of hematopoietic progeni-
tor cells is similar in UCB and in adult bone
marrow, however, the former contains a
higher proportion of primitive hematopoietic
cells, such as the multipotent colony forming
cells (Hows et al., 1992; Mayani et al., 1998),
long-term culture-initiating cells (Pettengell et
al., 1994) and SCID-repopulating cells (Wang
et al., 1997). It has been demonstrated that
the proliferative potential of UCB-derived
HSPC is higher than that of adult bone mar-
row or peripheral blood cells (Hows et al.,
1992; Traycoff et al., 1994; Mayani &
Lansdorp, 1998). Due to the low alloreactivity
of UCB lymphocytes the incidence and sever-
ity of the graft-versus-host disease after UCB
transplantation was reduced, when compared
to bone marrow grafts even in the case of par-
tially HLA-mismatched patients (Gluckman,
2000).
Gene therapy offers a strategy of treatment
ofvariousacquiredandgeneticdisorders.The
HSPC are an attractive target for gene incor-
poration, because they can be easily isolated,
genetically modified ex vivo and, after verify-
ingtheirfunctionalstatus,transplantedtothe
patient. The transplantation should result in
long-term repopulation of hematopoietic and
immune systems with a sufficient contribu-
tion of genetically modified cells (Capel et al.,
1990). However, for the two decades since the
development of gene delivery technology, for-
eign gene expression in HSPC has been diffi-
cult to achieve. A successful attempt of clini-
cal application of gene therapy has to involve
(i) optimisation of short-term culture condi-
tionspreventingapoptosisandsupportingthe
divisions of cells without a loss of their
pluripotency; and (ii) optimisation of gene
transfer strategy to increase its efficiency
without the reduction of cell viability and al-
terationofthefunctionalstatusoftheHSPC.
Several approaches have been taken to in-
corporate foreign DNA into HSPC. The most
commonly used are viral and nonviral vectors
delivered via different ways. Here we describe
transient transfection of HSPC by electro-
poration with efficiency comparable to that of
other DNA delivery methods.
MATERIALS AND METHODS
Cell isolation. Cord blood samples, col-
lected from full-term normal deliveries, were
diluted 1:1 with phosphate-bufferd saline
(PBS) (Gibco). Subsequently, mononuclear
cells were isolated by centrifugation on Ficoll
(Sigma; 1.077 g/ml) at 400  g for 40 min.
The mononuclear cells were collected, washed
twice in IMDM (Gibco) supplemented with
10% FCS (Cytogen) and resuspended in PBS
with the addition of 0.5% human serum albu-
min (HSA) (Biomed).
The CD34+ fraction was isolated immuno-
magnetically using MS+ MiniMACS columns
and the CD34 Direct Isolation Kit (Miltenyi
Biotec) according to the manufacturer recom-
mendations. In brief, after adding FcR
Blocking Reagent, cells were labelled with
MACS CD34 Microbeads for 30 min at
6–12C. Subsequently, the labelled cells were
enriched by passing the cell suspension
through a column placed in a magnetic field.
The positively selected cells were removed
from the magnetic field and washed out from
thecolumn.ThepurityoftheCD34+cellpopu-
lation was determined by flow cytometry im-
mediately after isolation.
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posttransfection incubation. Target cells
wereculturedin25cm2flasksatacelldensity
of 1  105/ml in a serum-free medium for
hematopoietic stem and progenitor cells
(CellGro) supplemented with growth factors:
stem cell factor (SCF) (20 ng/ml; PeproTech
EC), trombopoietin (TPO) (50 ng/ml;
PeproTech EC) and Flt-3 ligand (Flt-3L) (50
ng/ml; PeproTech EC). After 48 hours of in-
cubation at 37°C in a humidified atmosphere
of 5% CO2, cells were resuspended at 1 
105/ml in the CellGro medium supplemented
with 20% HSA. DNA plasmid (pEGFP-N2;
Clontech) carrying EGFP as a reporter gene
under control of the CMV promoter, was
added to the 400 l of cell suspension. The
electroporation was performed ina4m m
cuvette using a BTX ECL600 instrument
(Gentronix). The voltage was set at 550 V/cm.
The capacitances and the amount of DNA
used for electroporation are shown in Table 1
andTable2,respectively.Cellspulsedwithout
the presence of DNA served as a control. Im-
mediately after the electroporation cells were
transferred to fresh CellGro medium contain-
ing growth factors and incubated for 48 h at
37°C, 5% CO2. Subsequently, the transfection
efficiency was measured by flow cytometric
analysis of EGFP expression.
Flow cytometric analysis. The assayed
cells were acquisited using the FACS Calibur
flow cytometer (BD) equipped with an ar-
gon-ion laser tuned at 488 nm. The analysis
was performed by use of the CellQuest soft-
ware (BD).
For CD34+ cell quantitation the samples
were labelled with mouse monoclonal anti
CD34 antibody (anti HPCA-2, BD) directly
conjugated to phycoerythrin (PE). An isotype-
matched PE-conjugated antibody (IgG1)
servedasacontrol.Theflowcytometricanaly-
sis consisted in the exclusion of debris and
gating of the low-density cells on the forward
scatter (FSC) versus side scatter (SSC) dot
plot (Fig. 1). To estimate the percentage of
CD34+ cells, a second plot (SSC versus CD34+
fluorescence) was drawn and PE-positive cells
were gated. The absolute number of CD34+
cells was calculated on the basis of the total
number of nucleated cells.
Directly prior to flow cytometric acquisition,
the electroporated cells were stained for cell
viability assay with propidium iodide (PI) (50
g/ml; Sigma) according to the method de-
scribed by Wu et al. (2001b). The analysis
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Figure 1. Flow cytometric analysis of UCB-derived CD34
+ cells.
(A) Gating of cells and debris exclusion on a FSC/SSC dot plot; (B) evaluation of the frequency of non-specific anti-
body binding on a SSC versus IgG1-PE fluorescence dot plot of cells stained with control antibody; (C) evaluation of
thefrequencyofCD34
+cellsonaSSCversusCD34-PEdotplotofcellsstainedwithanti-CD34monoclonalantibody.(Fig. 2) consisted in gating of the cells on the
FSC/SSC dot plot for exclusion of contami-
nating debris and cell doublets. The gated
cells were subsequently evaluated by drawing
the second plot (EGFP fluorescence versus PI
fluorescence) for EGFP expression in the via-
ble cells. Representative flow cytometric anal-
yses of the CD34+ cells electropulsed with or
without plasmid DNA, showing their viability
and the expression of EGFP in the electro-
porated cells, are demonstrated in Figs. 2B
and 2C, respectively.
RESULTS
In our study we evaluated the effect of
electroporation conditions (pulse capacitance
and DNA concentration) on the transfection
efficiency and the viability of the UCB-derived
CD34+ cells. As demonstrated in Fig. 2C, cells
pulsed in the presence of the DNA and incu-
bated in the CellGro medium supplemented
withTPO/SCF/Flt-3Lfor48hshowedexpres-
sion of EGFP. The highest (over 40%) percent-
age of cells expressing the reporter gene was
observed among the CD34+ cells electro-
porated with the capacitances of 1600 F and
2400F.However,applicationofthelatterca-
pacitance resulted in a significant decrease of
cell viability (Table 1).
We also examined the effect of DNA concen-
tration on the effectiveness of gene delivery.
CD34+ cells were electroporated at the opti-
mal capacitance (1600 mF) and in the pres-
ence of various concentrations of plasmid
DNA. As it was clearly shown (Table 2), the in-
crease of transfection efficiency due to the ap-
plication of high plasmid DNA concentration
was paralleled by a decrease of cell viability.
DISCUSSION
Clinical application of genetically modified
CD34+ hematopoietic stem/progenitor cells
transplantation rapidly becomes an area of in-
tensive investigations. Gene therapy requires
an efficient and safe procedure of gene deliv-
eryintoHSPC.Thefirstattemptatgenedeliv-
ery into HSPC was the use of adenoviral or
retroviral vectors (Baum et al., 1996; Frey et
al., 1998). The main disadvantage of applica-
tion of viral vectors is the possibility of viral
infection and their immunogenicity. More-
over, adenoviral vectors are not suitable for
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Figure 2. Flow cytometric analysis of electroporated CD34
+ cells isolated from umbilical cord blood.
Gating of cells and debris exclusion on a FSC/SSC dot plot (A); evaluation of the transfection efficiency on the
EGFP expression versus PI fluorescence (cell viability) dot plot of cells electroporated without (B) or with (C)
plasmid DNA.the treatment of disorders requiring stable
gene integration into the genome of target
cells and the efficiency of retroviral vectors is
usually poor (Corrias et al., 1998). Virus-medi-
ated gene incorporation typically includes the
long-lasting stimulation with growth factors
(von Kalle et al., 1994), which causes HSPC
differentiation and loss of their self-renewing
capacity (Corrias et al., 1998). Moreover, a
number of diseases (i.e. some leukemias and
lymphomas) are resistant to virus-mediated
gene delivery (Brenner, 1997).
Electroporation is an attractive method of
gene transfer into HSPC for clinical applica-
tionsbecauseitisfreefrombiologicalcontam-
ination and possibility of immune reaction.
Electrotransfection results in sustained for-
eign gene expression in CD34+ cells (Ton-
eguzzo & Keating, 1986; Van Tendeloo et al.,
2000; Wu et al., 2001a). In this paper we re-
port the optimisation of gene incorporation
parameters into CD34+ cells derived from
UCB. Enrichment of CD34+ cells on immuno-
magnetic columns allowed us to perform the
experiments with a pure population of these
cells (Fig. 3). The plasmid carrying an en-
hanced version of green fluorescent protein
(EGFP)usedinourexperimentisafrequently
applied marker of gene incorporation (Chalfie
et al., 1994). Cells expressing this molecule be-
come fluorescent and detectable by flow
cytometry or fluorescent microscopy
(Bierhuizen et al., 1997; Limon et al., 1997;
Persons et al., 1997). To assess proliferating
cells, a condition necessary for non-retroviral
plasmidincorporationintothetargetgenome,
we stimulated cell divisions by the addition of
TPO, SCF and Flt-3L to a serum-free medium.
As reported previously, such medium pro-
motes rapid exit from G0 phase, but prevents
celldifferentiation(Lietal.,2001).Ithasbeen
demonstrated that short-term culture of
CD34+ cells in a TPO/SCF/Flt-3L serum-free
medium resulted in an increase of the cycling
CD34+cellsfractionandinaugmentingtheef-
ficiency of reporter gene transfer. Supple-
mentation of the serum-free medium with
other growth factor (IL-3) had no further ef-
fect on cell expansion and the efficiency of
gene delivery (Wu et al., 2001b). At the opti-
Vol. 49 CD34+ cells transfection 629
Table 1. The effect of electroporation capacitance on transfection efficiency and cell viability
Capacitance DNA Pulse length Viability Efficiency
F gm s% %
1600 0 38.4 83.1 0.0
1000 10 26.0 93.9 20.3
1200 10 31.8 89.3 23.4
1600 10 39.1 82.1 41.2
2400 10 62.0 68.8 43.3
Table 2. The effect of DNA amount on transfection efficiency and cell viability
Capacitance DNA Pulse length Viability Efficiency
F gm s% %
1600 0 40.2 86.5 0.0
1600 5 41.6 83.9 28.9
1600 10 42.7 76.7 38.7
1600 20 43.6 71.1 46.5mised conditions of electroporation (1600 F,
550V/cm,10gofplasmidDNAper400lof
cell culture) we obtained expression of the re-
porter gene (EGFP) in more than 40% of
treatedcells(Fig.4)withhighcellviability.Al-
though further increase of the pulse capaci-
tance and DNA concentration resulted in
higher transfection efficiency, it caused
greater cell death due to the “electroporation
toxicity” (Li et al., 2001). The obtained effi-
ciency of transfection of CD34+ cells isolated
from umbilical cord blood was comparable to
previous studies on UCB- (Wu et al., 2001c)
and peripheral blood-derived (Wu et al.,
2001a) HSPC and was higher than that deter-
mined for adult bone marrow cells (Van
Tendeloo et al., 2000). This high gene transfer
efficiency might be due to the immature sta-
tus of umbilical cord blood CD34+ cells. Some
authors suggest that transfection capacity of
more differentiated progenitors is lower than
withtheprimitivecells(Wuetal.,2001c).Fur-
ther investigations are necessary to evaluate
thecorrelationbetweenthehematopoieticcell
maturation and the efficiency of their
transfection. It is also of interest whether the
transfected CD34+ cells remain capable of for-
eign gene expression after their differentia-
tion into fully matured blood cells.
In conclusion, the high frequency of
transfection without a marked viability de-
crease justifies recommendation of electro-
poration as an efficient method of gene incor-
poration into UCB derived CD34+ cells.
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